Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study.
Chau I, Fakih M, García-Alfonso P, Linke Z, Ruiz Casado A, Marques EP, Picard P, Celanovic M, Cartwright T. Chau I, et al. Among authors: picard p. Cancers (Basel). 2020 Mar 11;12(3):657. doi: 10.3390/cancers12030657. Cancers (Basel). 2020. PMID: 32168980 Free PMC article.
Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Rosenstock J, et al. Among authors: picard p. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. Diabetes Care. 2021. PMID: 34183429 Free PMC article.
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Riechelmann RP, Srimuninnimit V, Bordonaro R, Kavan P, Di Bartolomeo M, Maiello E, Cicin I, García-Alfonso P, Chau I, Fedyanin MY, Martos CF, Ter-Ovanesov M, Peeters M, Ko YJ, Yalcin S, Karthaus M, Aparicio J, Heinemann V, Picard P, Bury D, Drea E, Sobrero A. Riechelmann RP, et al. Among authors: picard p. Clin Colorectal Cancer. 2019 Sep;18(3):183-191.e3. doi: 10.1016/j.clcc.2019.05.003. Epub 2019 May 15. Clin Colorectal Cancer. 2019. PMID: 31221542 Free article. Clinical Trial.
Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.
McCrimmon RJ, Home P, Cheng A, Giorgino F, Fonseca V, Souhami E, Alvarez A, Picard P, Rosenstock J. McCrimmon RJ, et al. Among authors: picard p. Diabetes Obes Metab. 2022 Dec;24(12):2391-2399. doi: 10.1111/dom.14825. Epub 2022 Aug 23. Diabetes Obes Metab. 2022. PMID: 36054624 Free PMC article.
A pandemic business interruption insurance.
Louaas A, Picard P. Louaas A, et al. Among authors: picard p. Geneva Risk Insur Rev. 2023;48(1):1-30. doi: 10.1057/s10713-023-00080-7. Epub 2023 Jan 25. Geneva Risk Insur Rev. 2023. PMID: 36712994 Free PMC article.
175 results